There are moments in the academic calendar when reading becomes something other than triage. The end of year 2025—when the inbox slows, deadlines loosen, and the professional reflex to read “for…
This second contribution completes the analysis developed in Part 1. Building on the product-centred reasoning adopted by the District Court of The Hague, it examines the limits of that approach in…
I am particularly pleased to publish this commentary, co-authored with my friend and colleague Marco Stief, whose earlier work on this decision provided the starting point for the present analysis,…
Today, I would like to offer a review of Léon Dijkman’s The Proportionality Test in European Patent Law and the UPC, a timely and ambitious contribution to the fast-evolving law of patent remedies in…
An offer you can refuse?The recent judgment in Teva/Cephalon firmly anchors EU jurisprudence on pay-for-delay agreements. By upholding the sanctions imposed on the two companies for a series of side…
The UPC Paris Local Division has just released its much-anticipated decision in Merz v. Viatris, which at first glance looks like a familiar pharmaceutical case. A generic product moves through the…
Two years after its launch, the Unified Patent Court has moved from promise to practice. What once looked like a procedural experiment has become a credible, fast, and intellectually rigorous forum…
For months, commentary on Boehringer has flourished across the European patent community. Yet amid the noise, the fundamental question—what the decision truly changes in the logic of injunctions…
At the AIPPI, irony sometimes writes itself. In 2020, when the Association launched its essay competition, I submitted a paper on compulsory licenses and legitimacy — optimistically entitled “COVID…
